For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | 6,834 | -417* | 6,136 | 24,091 |
| General and administrative | 3,271 | 3,677* | 2,809 | 3,201 |
| Total operating expenses | 10,105 | 3,259 | 8,945 | 27,292 |
| Loss from operations | -10,105 | -3,259* | -8,945 | -27,292 |
| Other income, net | 309 | 565* | 321 | 484 |
| Net loss | -9,796 | -2,695* | -8,624 | -26,808 |
| Unrealized gain on marketable securities | -23 | -8* | 24 | -7 |
| Total comprehensive loss | -9,819 | -2,704 | -8,600 | -26,815 |
| Basic EPS | -1.87 | -0.778 | -3.22 | -11.29 |
| Diluted EPS | -1.87 | -0.778 | -3.22 | -11.29 |
| Basic Average Shares | 5,239,236 | 3,476,499 | 2,676,116 | 2,374,729 |
| Diluted Average Shares | 5,239,236 | 3,476,499 | 2,676,116 | 2,374,729 |
NextCure, Inc. (NXTC)
NextCure, Inc. (NXTC)